Provides an oral Disintegration Tablet obtained by compression of Fine Granules which showed a controlled release of lansoprazole and an Additive.That is capable of suppressing the breakage of the fine Granules during Compression and can control the release of lansoprazole for a long time and can keep a therapeutically effective concentration for a long time and shows a property of Disintegration in the Oral cavity.An oral disintegrating Tablet containing (i) fine Granules that show a controlled release of a pharmaceutically Active Ingredient, containing Fine Granules with a pharmaceutically Active Ingredient, and a coating layer with methacrylic acid COPOLYMER / Methyl acrylate / Methyl methacrylateWhere the fine Granules containing a pharmaceutically Active Ingredient are coated with more than 80% by weight and not more than 300% by weight of the Copolymer and (ii) fine Granules that show a controlled release of a pharmaceutically Active Ingredient,Which contains the pharmaceutically Active Ingredient and a coating layer comprising (a) a Copolymer of Ethyl acrylate / Methyl methacrylate and (b) one or more types of Polymers selected from the group consisting of methacrylic acid Copolymer / acrylate, Ethyl phthalate Hypromellose, carboximetiletilcelulosa, Polyvinyl Acetate Phthalate,Hydroxypropyl methylcellulose acetate succinate and acetate Phthalate Cellulose, where the Granules Granules Fine Fine (i) and (ii) have a mean particle size of not more than 500 pm and the pharmaceutically Active Ingredient is lansoprazole or one of its forms or optically Active Of their Salts.Se proporciona un comprimido de desintegración oral obtenido por compresión de gránulos finos que muestran una liberación controlada de lansoprazol y un aditivo, que es capaz de suprimir la rotura de los gránulos finos durante la compresión y puede controlar la liberación de lansoprazol durante un tiempo prolongado y puede mantener una concentración terapéuticamente efectiva durante un tiempo
